News Releases

Sep 04, 2022 CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the AeriSeal System REDWOOD CITY, Calif. & BARCELONA, Spain --(BUSINESS WIRE)--Sep.
Aug 24, 2022 Pulmonx to Present at Upcoming September Investor Conferences
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Aug. 24, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in fireside chats at two upcoming investor conferences.
Aug 02, 2022 Pulmonx Reports Second Quarter 2022 Financial Results
REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter ended June 30, 2022.
Jul 27, 2022 Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston .
Jul 19, 2022 Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jul. 19, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday,
May 03, 2022 Pulmonx Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter ended March 31, 2022.
Apr 26, 2022 Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference
REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Bank of America Securities 2022 Healthcare Conference in Las
Apr 19, 2022 Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Tuesday, May
Feb 23, 2022 Pulmonx Reports Fourth Quarter and Full Year 2021 Financial Results
REDWOOD CITY, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2021 ended December 31, 2021.
Feb 10, 2022 Pulmonx to Present at the Citi 2022 Virtual Healthcare Conference
REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2022 Virtual Healthcare Conference on
Displaying 1 - 10 of 11
Print Page
Email Alerts
Contact IR
RSS Feeds